The American Cancer Society reports that prostate cancer ranks as the second most common cause of cancer-related deaths among men in the U.S., trailing only lung cancer. Statistically, about 1 in 8 men will face a prostate cancer diagnosis at some point in their lifetime. While treatment options exist for most cases, some forms of the disease prove resistant to all known therapies, leading to dire outcomes. However, recent research using mouse models suggests that a precursor to vitamin K may help slow the progression of prostate cancer.

Breakthrough Research on Vitamin K and Cancer

Scientists at Cold Spring Harbor Laboratory have made a promising discovery that could change the way prostate cancer is treated. Under the leadership of Professor Lloyd Trotman, researchers found that menadione, a pro-oxidant supplement commonly found in leafy greens, significantly reduces prostate cancer growth in mice. Menadione serves as a precursor to vitamin K, and while this particular study is new, it builds upon research conducted in the early 2000s.

Vitamin E and Prostate Cancer: A Shift in Perspective

A 2001 study by the National Cancer Institute set out to determine whether vitamin E, an antioxidant, could prevent or treat prostate cancer. Originally planned to span 12 years with 35,000 participants, the trial was abruptly halted after just three years. The reason? Not only did vitamin E fail to curb the disease, but it actually led to an increase in prostate cancer cases among the participants.

A New Approach involving Mice